Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

Imatinib mesylate (IM) is a small molecule inhibitor of protein tyrosine kinases. In addition to its direct effect on malignant cells, it has been suggested IM may activate of natural killer (NK) cells, hence exerting immunomodulatory functions. In preclinical settings, improved antitumor responses...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Pautier, Patricia, Locher, Clara, Robert, Caroline, Deroussent, Alain, Flament, Caroline, Le Cesne, Axel, Rey, Annie, Bahleda, Ratislav, Ribrag, Vincent, Soria, Jean-Charles, Vassal, Gilles, Eggermont, Alexander, Zitvogel, Laurence, Chaput, Nathalie, Paci, Angelo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Landes Bioscience 2013
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3601177/
https://ncbi.nlm.nih.gov/pubmed/23525192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.23079
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi